Definium Therapeutics, Inc. Q4 FY2025 earnings call

Rob Barrow discussed progress in clinical programs, including DT120 ODT's Phase III studies with Emerge fully enrolled and data expected in late Q2, Ascend starting soon, Voyage near enrollment completion, and Panorama progressing. Dan Karlin provided details on study designs and enrollment. Matt Wiley talked about commercial readiness. Brandi Roberts reviewed financials

R&D expenses in 2025 were $117.7 million, up from $65.3 million in 2024. G&A expenses were $48.6 million, up from $38.6 million. Net loss was $183.8 million. Cash, cash equivalents and investments ended 2025 at $411.6 million

2026 expected to be pivotal with 3 Phase III readouts. Cash as of 2025 sufficient to fund operations into 2028. Planning to accelerate NDA preparation, market access, etc.

Risks include changes in market conditions, difficulties in R&D and regulatory approval processes

Q: Hypothetical scenario on upsizing Voyage trial.

A: Blinded sample size re-estimation, no implication of futility or success.

Q: Interim looks for Panorama and Emerge.

A: Details on interim analysis plans.

Q: GAD remission rate expectations.

A: Discussion on remission rate and severity impact.

Q: Enrollment and incremental confidence for trials.

A: Updates on enrollment and confidence factors.

Q: Potential filing strategy and DT402.

A: Talk on filing strategy and DT402's clinical effect measures.

Q: MDD quality of life metrics.

A: Discussion on WPAI and patient productivity.

Q: Panorama European sites variability.

A: Addressing diagnostic and practice variation.

Q: MDD commercial profile and regulatory.

A: Thoughts on MDD commercial profile and regulatory landscape.

Q: Durability and commercial pricing.

A: Discussion on durability importance and pricing thoughts